OPEN Health’s Post

Has the #COVID-19 #pandemic impacted long-term therapies, and if so, has the effect been negative or positive? Delve deeper into our recent analysis of #statin usage in Poland during the pandemic, utilizing data from the national #prescription and #dispensing database encompassing 38 million individuals.

We’re delighted to share our published research paper with Frontiers, titled, ‘Development and deployment of nationwide predictive model for chronic kidney disease progression in diabetic patients’. Frontiers is one of the largest global research publishers. Did you know that around 25% - 40% of patients with diabetes develop chronic kidney disease (CKD), and it is projected to be the fifth leading cause of death globally by 2040? CKD is usually diagnosed late as it often shows no symptoms in the early stages. This reseach paper successfully proves how an artificial intelligence-based model can be adopted to help clinicians identify patients with early stages of CKD and to provide early intervention to avert or delay kidney function deterioration. Not only is our CKD model rigorously validated, but it is also the first clinical model deployed nationwide in Singapore and incorporated into a national programme to engage patients in long-term care plans in battling chronic diseases. A shout-out to the collaborative efforts from Adrian Liew, Ang Gia Lee, Anthony Wee, Chee Kong Lim, Chow Wai leng, Karen Clemente, Ken Poon, Majorie Wai, Mohit Jaisinghani, Zhiyan Fu, Zhiyu (Beverly) Wang, the Synapxe team, Ministry of Health (Singapore), and partners National Healthcare Group, Singapore General Hospital, and Mount Elizabeth Hospitals, Singapore who made this possible! Read the full research here: https://rb.gy/sp1pmn #InspiringTomorrowsHealth #ChronicKidneyDisease #CKD #CKDprevention #HealthierSG #Synapxe

New data at #ECO2024 on #semaglutide heart health benefits and long-term weight outcomes present a compelling picture of clinical benefits. https://lnkd.in/eWMHgwpm

Check out our work on point-of-care liver health diagnostics at the University of Edinburgh, and please participate in the surveys. #innovation #healthcare #medtech #invitrodiagnostics #pointofcaretesting #ICUReExplore #InnovateUK #UoE

With over 400,000 people in Singapore living with diabetes and this number being projected to rise to one million by 2050, the need for early detection and management of diabetes-related kidney failure is more critical than ever. Developed by NHG and SingHealth/Singapore General Hospital (SGH), in collaboration with industry partner Mesh Bio, HealthVector Diabetes is a digital twin-based software leveraging computational systems biology and artificial intelligence to predict the risk of chronic kidney disease (CKD) onset over three years in patients with type 2 diabetes. Using this software, clinicians will be able to sooner identify those at risk and tailor personalised interventions according to each patient’s needs. Read on to find out more about how this software will help patients achieve better health outcomes and quality of life in the link below. #NHGinthenews https://lnkd.in/giBtjj4u

Two itchy-skin diseases that can go much deeper: Psoriasis and eczema can have complex causes and consequences that researchers are seeking to uncover. #HIPPOCRATES_IMI and BIOMAP IMI featured in this great article by Gareth Willmer published in the Horizon Magazine Research and Innovation. Have a read! https://lnkd.in/evXi7DHe Innovative Health Initiative (IHI) EU Science, Research and Innovation

🌟 Excited to share our groundbreaking report, "Beyond Skin-Deep: Tackling Gaps in Psoriasis Care," to which I had the privilege to contribute! 🌟 Thrilled to have been part of the dedicated research team behind this insightful report, commissioned and supported by Bristol Myers Squibb. This comprehensive study explores the challenges and opportunities across the psoriasis care pathway in eight countries, highlighting ways health systems can better meet patients' needs. Key findings from the report: 📊 The economic and societal burden of psoriasis is substantial, impacting work-related productivity and incurring significant indirect costs for patients. 🌍 Access to innovative, high-cost therapies often depends on regional health funding, leading to disparities in care delivery. 🗣️ Patient advocate-led efforts are vital for greater recognition of psoriasis in public health policy, yet face challenges due to public perception and lack of alignment in treatment guidelines. Acknowledgments: A heartfelt thank you to Kati Chilikova, M.Sc. for her exceptional leadership as the project manager, and to Alcir Santos Neto and Loreta De Rossi Guerra for their invaluable contributions to the research process. Your dedication and expertise were instrumental in shaping this report. Gratitude also to Latifat Okara and Amanda Stucke, MPH for their guidance and support as project directors. Your vision and commitment were pivotal in bringing this report to fruition. The insights and perspectives presented in this report aim to spark meaningful conversations and drive positive change in psoriasis care. I invite you to read the full report and join the dialogue on how we can collaboratively address the gaps in psoriasis care. Together, let's make a difference in the lives of those affected by psoriasis! 📄 https://lnkd.in/er7bwSiq #PsoriasisCare #Healthcare #Research #PatientCare #HealthSystems #EconomistImpact #BristolMyersSquibb

Hereditary Hemochromatosis: Understanding its impact and care! My published article at the site. Give it a read and stay tuned to know more about health issues. #publishedwork #sehathub #Healthwriting #medicalwriting

Digital twins set the stage for informed decision-making in planning, operation, and maintenance scenarios, from engineering to industrial. In light of the accumulation of data, the comprehension of mechanisms, and the advancement in machine learning, the concept is becoming relevant to drug & biomarker discovery, clinical trials, personalised medicine & treatment, wellness, etc., in healthcare. Sophistication in pharmacology, physiology, and MIDD[1] makes population-level predictions via virtual patient cohorts possible, economically speeding up the work required. Leveraging omics data, phenotyping, RWD[2], and algorithms, we can move forward to construct plausible patient cohorts that promote understanding of MoA[2] in diseases and individual-level predictions. In clinical trials, this could optimise the size of the control group while maintaining statistical purposes. In clinical practice, this could notify about early intervention and preventative care. There are a variety of organ and disease models, ranging from straightforward cardiovascular to complex immuno-oncology cohort generation. Interconnected modelling can serve as a study approach. Regulatory support for digital twins varies, whereas the work can be multidisciplinary and is not without challenges. There is no lack of coverage on this topic. People-less trials and whole-body replicas might be fictional, but unconventional thinking with rigorous assessment and ethics can be instrumental. IEEE Prediction 2024 classifies “digital twins for vertical applications” as broad adoption. https://lnkd.in/g2ij3jCH Non-business-related innovation trend spotting. Foresight does not necessarily describe the exact details of the quoted work, courtesy of the quoted vendor, healthcare clusters, and various sources. [1] model-informed drug development [2] real-world data [3] mechanism of action

Our innovative case-finding tool hepatoSIGHT has played a pivotal role in advancing medical research in liver disease. Last year alone, researchers used hepatoSIGHT in several important studies, here are just 3: 1. Identifying Chronic Liver Disease in Deprived Areas: Our collaborators at Somerset NHS Foundation Trust used hepatoSIGHT to proactively reach out to individuals in deprived areas at a high risk of chronic liver disease. The study found that those in deprived areas displayed more indicators of fibrosis and decompensation, and crucially, were adequately represented in the existing data. This study demonstrates the impact that a tool like hepatoSIGHT could have on improving care for disadvantaged members of society. 2. Informing Hepatitis B Strategies in Deprived Areas: Configured to identify people likely to have Hepatitis B, hepatoSIGHT revealed a higher prevalence of Hep B in deprived areas. Challenges in engagement and follow-up in deprived areas were identified, underscoring the importance of improving investigation and referral pathways. The tool's application in this study demonstrates its use, not just in clinical interventions, but also in informing medical research aimed at eliminating Hepatitis B by 2030. 3. Uncovering Under-Investigated Liver Conditions: The hepatoSIGHT tool was employed to identify patients with persistently abnormal liver chemistry, revealing under-investigation of chronic liver diseases. The study exposed missed opportunities for treatment, with just 1 in 10 people with signs of liver issues receiving adequate follow-up. Our case-finding database rapidly identified thousands of individuals who might benefit from further investigation. Get in touch and learn more about hepatoSIGHT 👇https://lnkd.in/eSMDDMPu #liverdisease #medicalresearch #viralhepatitis